Deflationary “race‑to‑the‑bottom” competition drives many essential generics below sustainable cost, prompting market exits and reduced investment, particularly for low‑priced sterile injectables.
Ultimately, I believe AI advantage will be defined by how intelligently organizations allocate tokens, compute and energy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results